Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C …

Sorafenib increases overall survival in patients with advanced HCC by almost three months.
However, despite these advances in the treatment of patients with HCC, average overall …

Seven years have passed since sorafenib was approved as a systemic chemotherapeutic
agent that improves survival in patients with advanced hepatocellular carcinoma (HCC) …

Background Intra-patient variability in sorafenib pharmacokinetics has been poorly
investigated to date. We hypothesized that sorafenib clearance could decrease over time, as …

Medical therapies have entered center stage in the treatment of hepatocellular carcinoma
(HCC) little more than a year after the positive results of a large phase III trial of sorafenib …

Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC)
treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent findings suggest that …

Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma
(HCC). The management of its side effects is improving. This study aimed to assess, in real …

Opinion statement Hepatocellular carcinoma (HCC) is one of the most lethal cancers
globally, particularly in certain regions of the world. Although the major risk factors for HCC …

Primary liver cancer is the fifth most common cancer worldwide and the third most common
cause of death from cancer, resulting in more than 600,000 deaths per year. The major risk …

Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced
hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC …